Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small cell lung cancer
- VernacularTitle:斯鲁利单抗联合化疗方案一线治疗广泛期小细胞肺癌的药物经济学评价
- Author:
Ran QI
1
;
Xuyang NIE
2
;
Xuting LIU
1
;
Shengnan GAO
1
;
Guoqiang LIU
1
Author Information
1. Dept. of Clinical Pharmacy，the Third Hospital of Hebei Medical University，Shijiazhuang 050051，China
2. Dept. of Clinical Pharmacology Research，the Fourth Hospital of Hebei Medical University，Shijiazhuang 050011，China
- Publication Type:Journal Article
- Keywords:
serplulimab;
extensive-stage small cell lung cancer;
first-line chemotherapy;
partitioned survival model;
cost-
- From:
China Pharmacy
2023;34(11):1368-1373
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the economics of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small cell lung cancer （ES-SCLC） from the perspective of health system in China. METHODS A partitioned survival model was constructed based on the ASTRUM-005 clinical trial and related literature data， with a model simulation time frame of 10 years and a 3-week cycle， and both cost and utility values were discounted using a 5% discount rate. The quality-adjusted life year （QALY） was used as a model output indicator and the incremental cost-effectiveness ratio （ICER） was calculated to evaluate the economics of serplulimab combined with chemotherapy regimens （serplulimab group） versus chemotherapy alone regimens （chemotherapy alone group） for the first-line treatment of ES-SCLC. One-way sensitivity analysis and probabilistic sensitivity analysis were used to verify the robustness of the results of the base-case analysis and to conduct a scenario analysis for the serplulimab patient assistance program. RESULTS The results of the base-case analysis showed that compared with chemotherapy alone group， ICER of serplulimab group was 758 690.27 yuan/QALY， which was higher than 3 times China’s per capita gross domestic product （GDP） in 2022 as the willingness-to-pay （WTP） threshold. The results of the scenario analysis showed that compared with chemotherapy alone group， the ICER of serplulimab group was 172 275.74 yuan/QALY， which was below above WTP threshold. The one-way sensitivity analysis showed that the progress-free survival utility value， serplulimab price and so on had a significant impact on the model results. The results of the probabilistic sensitivity analysis showed that the probability of the serplulimab group being economic was 0 when the serplulimab patient assistance program was not considered， but 100% when the patient assistance program was considered. CONCLUSIONS At a WTP threshold of 3 times China’s per capita GDP in 2022， the serplulimab group is no cost-effectiveness compared to the chemotherapy alone group； however， this result is reversed when the patient assistance program is taken into account.
